Alamar Biosciences, Inc. has secured $50.0 million in new investment capital from investors. This funding round marks a significant milestone for the company, which is focused on advancing precision proteomics through its innovative automated solutions for protein analysis.
The company specializes in powering precision proteomics with automated, high-throughput solutions designed for ultra-high sensitivity protein analysis across a range of multiplex levels. At the core of its technology is the proprietary NULISA™ Chemistry. This method utilizes a novel sequential capture and release approach that significantly reduces background signal, thereby increasing sensitivity and dynamic range compared with standard techniques. NULISA™ Chemistry also offers versatility, allowing for both qPCR and NGS readouts. Alamar Biosciences' product pipeline includes the NULISAseq Inflammation Panel, which features over 200 important markers related to immune and inflammatory diseases, designed to run on its ARGO™ System. The ARGO™ System provides a fully automated workflow, requiring less than 30 minutes of hands-on time from sample to data.
This substantial capital infusion is intended to accelerate the company's strategic growth initiatives. Alamar Biosciences plans to use the funds to further advance its research and development efforts, scale its manufacturing capabilities, and expand the commercialization of its NULISA™ platform and ARGO™ System. The investment underscores confidence in Alamar Biosciences' technology and its potential to address critical needs in the proteomics market.
The successful completion of this funding round positions Alamar Biosciences to broaden its market presence and enhance its offerings. The company aims to continue innovating in the field of protein analysis, supporting researchers and clinicians with tools that enable more precise and efficient insights into complex biological processes, ultimately contributing to advancements in disease understanding and treatment.
